EGFR status and prognosis of patients with locally advanced head and neck cancer treated with chemoradiotherapy

Anticancer Research

Volumn 30, Issue 2, 2010, Pages 671-676

  Numico, Gianmauro ^a   Russi, Elvio Grazioso ^b   Colantonio, Ida ^b   Lantermo, Rosa Anna ^b   Silvestris, Nicola ^c   Vitiello, Raffaele ^b   Comino, Alberto ^b   Abrate, Mario ^d   Zavattero, Carla ^d   Melano, Antonella ^b   Merlano, Marco ^b  

^a Aosta Hospital   (Italy)

^b S CROCE E CARLE HOSPITAL   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^d Ospedale SS Annunziata   (Italy)

Author keywords

Chemoradiotherapy; EGFR; Head and neck cancer; Prognostic factor; Treatment

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 77950534860     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Forastiere A, Koch W, Trotti A and Sidransky D: Head and neck cancer. N Engl J Med 345: 1890-1900, 2001.
2. Pignon P, Bourhis J, Domenge C and Designé L, on behalf of the MACH-NC Collaborative Group: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355: 949-955, 2000.
3. Maurizi M, Almadori G, Ferrandina G, Distefano M, Romanini ME, Cadoni G, Benedetti-Panici P, Paludetti G, Scambia G and Mancuso S: Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 74: 1253-1257, 1996.
4. Grandis RJ, Melhem MF, Gooding WE, Day R, Holst VA, Wagener NM, Drenning SD and Tweardy DJ: Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90: 824-832, 1998.
5. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK and Milas L: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350-7356, 2002.
6. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarret C, Carter J, Murphy BA, Netterville J, Burkey BB, Sinard R, Cmelak A, Levy S, Yarbrough WG, Slebos RJC and Hirsch FR: Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24: 4170-4176, 2006.
7. Muller S, Su L, Tighiouart M, Saba N, Zhang H, Shin DM and Chen Z: Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma. Predictive and prognostic correlation. Cancer 113: 97-107, 2008.
8. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK and Milas L: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5: 2884-2890, 1999.
9. Liang K, Ang KK, Milas L, Hunter N and Fan Z: The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57: 246-254, 2003.
10. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K and Schmidt-Ullrich R: Radiation-induced release of transforming growth factor activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Cell Biol 10: 2493-2506, 1999.
11. Barker II FG, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, Wara WM, Berger MS, Chen P, Israel MA and Aldape KD: EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51: 410-418, 2001.
12. Gaffney DK, Haslam D, Tsodikov A, Hammond E, Seaman J, Holden J, Lee RJ, Zempolich K and Dodson M: Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overal survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 56: 922-928, 2003.
13. Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI, Trott KR and Wilson GD: Epidermal growth factor receptor expression in pre-treatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23: 5560-5567, 2005.
14. Eriksen JG, Steiniche T, Askaa J, Alsner J and Overgaard J: The prognostic value of epidermal growth factor receptor is related to tumor cell differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 58: 561-566, 2004.
15. Merlano M: Alternating chemotherapy and radiotherapy in locally advanced head and neck cancer: an alternative? Oncologist 11: 146-151, 2006.
16. Merlano M, Vitale V, Rosso R, Corvò R, Cavallari M, Sanguineti G, Bacigalupo A, Badellino F and Margarino G: Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 327: 1115-1121, 1992.
17. Merlano M, Russi EG, Numico G, Colantonio I, Garrone O, Pelissero A, Granetto C, Gasco M, Di Costanzo G, Heouaine A, Vigna Taglianti R and Cipolat M: Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck. A phase II trial. Radiother Oncol 75: 193-196, 2005.
18. Numico G, Russi EG, Vitiello R, Sorrentino R, Colantonio I, Cipolat M, Vigna Taglianti R, Pelissero A, Fea E, Granetto C, Di Costanzo G, Gasco M, Garrone O, Occelli M and Merlano M: Gemcitabine and cisplatin in a concomitant - alternating chemoradiotherapy program for locally advanced head and neck cancer: a pharmacology-guided schedule. Int J Radiat Oncol Biol Phys 66: 731-737, 2006.
19. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, Demard F and Milano G: Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11: 1873-1878, 1993.
20. Pivot X, Magné N, Guardiola E, Poissonnet G, Dassonville O, Francoual M, Formento JL, Bensadoun RJ, Demard F, Schneider M and Milano G: Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. Oral Oncol 41: 320-327, 2005.
21. Chua DT, Nicholls JM, Sham JS and Au GKH: Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 59: 11-20, 2004.
22. Kalyankrishna S and Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24: 2666-2672, 2006.
23. Corvò R, Giarretti W, Sanguineti G, Geido E, Bacigalupo A, Orecchia R, Benasso M, Numico G, Merlano M, Margarino G and Vitale V: Chemoradiotherapy as an alternative to radiotherapy alone in fast proliferating head and neck squamous cell carcinomas. Clin Cancer Res 3: 1993-1997, 1997.
24. Adelstein DJ, Saxton JP, Rybicki LA, Esclamado RM, Wood BJ, Strome M, Lavertu P, Lorenz RR and Carroll MA: Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 24: 1064-1071, 2006.
25. Fischer C, Zlobec I, Stockli E, Probst S, Stork C, Tornillo L, Lugli A, Wolfensberger M and Terracciano L: Is immunohistochemical epidermal growth factor receptor expression overestimated as a prognostic factor in head-neck squamous cell carcinoma? A retrospective analysis based on a tissue microarray of 365 carcinomas. Hum Pathol 39: 1527-1534, 2008.